Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia
Authors:
- 3 December 2013
- journal article
- clinical trial
- Published by Wiley in Transfusion
- Vol. 54 (6) , 1542-1551
Abstract
Background: Transfusional iron overload and its consequences are challenges in chronically transfused patients with myelodysplastic syndromes (MDSs) or aplastic anemia (AA).Study Design and Methods: This was a prospective, multicenter, open‐label study to investigate the efficacy of deferasirox (DFX) by serial measurement of serum ferritin (S‐ferritin) level, liver iron concentration (LIC) level using relaxation rates magnetic resonance imaging, and other laboratory variables in patients with MDS or AA.Results: A total of 96 patients showing S‐ferritin level of at least 1000 ng/mL received daily DFX for up to 1 year. At the end of the study, S‐ferritin level was significantly decreased in MDS (p = 0.02366) and AA (p = 0.0009). LIC level was also significantly reduced by more than 6.7 mg Fe/g dry weight from baseline. Hemoglobin level and platelet counts were significantly increased from baseline (p = 0.002 and p = 0.025, respectively) for patients showing significant anemia or thrombocytopenia. Elevated alanine aminotransferase was also significantly decreased from baseline.Conclusions: This study shows that DFX is effective in reducing S‐ferritin and LIC level in transfusional iron overload patients with MDS or AA and is well tolerated. In addition, positive effects in hematologic and hepatic function can be expected with DFX. Iron chelation treatment should be considered in transfused patients with MDS and AA when transfusion‐related iron overload is documented.Keywords
This publication has 33 references indexed in Scilit:
- Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC studyHaematologica, 2013
- Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal CohortBlood, 2012
- Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesHaematologica, 2012
- The many faces of the octahedral ferritin proteinBioMetals, 2011
- Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapyTransfusion, 2010
- Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overloadInternational Journal of Hematology, 2008
- Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective studyEuropean Journal of Haematology, 2007
- Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patientsEuropean Journal of Haematology, 2005
- Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2003
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994